

Mutations in *Mcoln3* associated with deafness and pigmentation defects in varitint-waddler (*Va*) mice

Federica Di Palma*, Inna A. Belyantseva[†], Hung J. Kim*[‡], Thomas F. Vogt^{§¶}, Bechara Kachar[†], and Konrad Noben-Trauth*^{||}

*Section on Neurogenetics, Laboratory of Molecular Biology, National Institute on Deafness and Other Communication Disorders, National Institutes of Health, 5 Research Court, Rockville, MD 20850; [†]Section on Structural Cell Biology, Laboratory of Cell Biology, National Institute on Deafness and Other Communication Disorders, National Institutes of Health, 50 Convent Drive, Bethesda, MD 20892; and [§]Department of Molecular Biology, Princeton University, Princeton, NJ 08544

Edited by Jeremy Nathans, The Johns Hopkins University School of Medicine, Baltimore, MD, and approved September 3, 2002 (received for review July 18, 2002)

Deafness in spontaneously occurring mouse mutants is often associated with defects in cochlea sensory hair cells, opening an avenue to systematically identify genes critical for hair cell structure and function. The classical semidominant mouse mutant varitint-waddler (*Va*) exhibits early-onset hearing loss, vestibular defects, pigmentation abnormalities, and perinatal lethality. A second allele, *Va'*, which arose in a cross segregating for *Va*, shows a less severe phenotype. By using a positional cloning strategy, we identify two additional members of the mucolipin gene family (*Mcoln2* and *Mcoln3*) in the 350-kb *Va'* minimal interval and provide evidence for *Mcoln3* as the gene mutated in varitint-waddler. *Mcoln3* encodes a putative six-transmembrane-domain protein with sequence and motif similarities to the family of nonselective transient-receptor-potential (TRP) ion channels. In the *Va* allele an Ala419Pro substitution occurs in the fifth transmembrane domain of *Mcoln3*, and in *Va'*, a second sequence alteration (Ile362Thr) occurring in cis partially rescues the *Va* allele. *Mcoln3* localizes to cytoplasmic compartments of hair cells and plasma membrane of stereocilia. Hair cell defects are apparent by embryonic day 17.5, assigning *Mcoln3* an essential role during early hair cell maturation. Our data suggest that *Mcoln3* is involved in ion homeostasis and acts cell-autonomously. Hence, we identify a molecular link between hair cell physiology and melanocyte function. Last, *MCOLN2* and *MCOLN3* are candidate genes for hereditary and/or sporadic forms of neurosensory disorders in humans.

Perception and transmission of acoustic stimuli in the mammalian cochlea is a stratified process involving the establishment of the endolymph through melanocytes located in the stria vascularis; deflection of stereocilia situated on the apical surface of sensory hair cells in the organ of Corti (OC); opening of mechanosensitive transduction channels, nonselectively permeable for cations, including Ca^{2+} ; and transmission of the electrical impulse onto the eighth cranial nerve for further processing in the auditory brainstem and cortex. Mutations affecting these processes are often associated with circling behavior, ataxic movements, and pigmentation anomalies. Circling and waltzing phenotypes are usually caused by mutations primarily affecting structure and function of hair cells, which, directly or indirectly, lead to stereocilia disorganization and hair cell degeneration. Genes critical for hair cells encode a functionally heterogeneous group of proteins that include structural proteins (myosins, cadherins, and spectrins), extracellular matrix proteins (tectorins), transmembrane proteins (channels, pumps, ion pores, and exchangers), and others (for review see ref. 1). Among the many coat color and spotting mutants, dominant spotting (*Kit^W*), steel (*Kit^{Sl}*), microphthalmia (*Mitf^{mi}*), and varitint-waddler (*Va*), exhibit deafness in combination with pigmentation defects. The genes underlying *W*, *St*, and *mi* have been shown to encode the c-Kit receptor tyrosine kinase (2, 3), its ligand Kitl (4, 5), and the *Mitf* transcription factor (6), respectively. Mutations in *Kit* and *Mitf* impair the survival of melanocytes in the

stria vascularis, resulting in the loss of the endochochlea potential, and deafness (7, 8).

To identify genes important for hair cell function, we adopted a positional cloning approach of mouse mutations with known defects in the OC. Two mutations, *Va* and *Va'*, arose spontaneously at the varitint-waddler locus, causing a distinct allele-specific set of phenotypes (9–11). Most severely affected are *Va/Va* mice, which exhibit deafness, circling behavior, sterility, an almost entirely white coat color, and reduced viability (9). The mildest phenotype is seen in *+/Va'* mice, which are viable, show normal vestibular function, display only limited variegation and coat color dilution, and have some residual hearing (10, 12, 13). *Va'/Va'* and *+/Va* mice show intermediate and similar phenotypes. Hearing tests and anatomical studies associated hearing loss in *Va'* mice with a primary defect in the sensory epithelium and reduced pigmentation in melanocytes located in the stria vascularis (12). These defects were found to occur independently, suggesting that *Va* acts as a cell-autonomous factor. Thus, unlike other spotted deaf mouse mutants (*Mitf^{mi}*, *Kit^W*, and *Kit^{Sl}*), in which neuroepithelial degeneration develops secondary to the stria vascularis defects, *Va* might reveal an interesting cellular and molecular principle shared by inner ear hair cells and melanocytes.

Materials and Methods

Mice and DNA. Mutant and common inbred mouse strains were obtained from The Jackson Laboratory. B6Fe-*a/a-Hoxa13Hd Va'* mice were backcrossed to the C57BL/6J strain for 10 generations and outcrossed to C3HeB/FeJ, and the resulting progeny were intercrossed. RSV/Le-*Va*/+ mice were outcrossed to C3HeB/FeJ and then intercrossed. Intercrossed offspring from *Va* and *Va'* strains were used for phalloidin staining and immunocytochemistry. Genomic DNA was obtained from The Jackson Laboratory. Animal care and procedures were in accordance with National Institutes of Health guidelines (Animal Study Protocol 821/97).

Physical Map. The physical map was constructed by screening the ES-129/SvJ I (Incyte Genomics, Palo Alto, CA) and the C57BL/6J RPCI-23 (Roswell Park Cancer Institute) mouse

This paper was submitted directly (Track II) to the PNAS office.

Abbreviations: TRP, transient receptor potential; BAC, bacterial artificial chromosome; IHCs, inner hair cells; OHCs, outer hair cells; OC, organ of Corti; Pn, postnatal day *n*; En, embryonic day *n*.

Data deposition: The sequences reported in this paper have been deposited in the GenBank database (accession nos. AC068974, AC079941, AY083531, AY083532, and AY083533).

See commentary on page 14613.

[†]Present address: Department of Otolaryngology and Head and Neck Surgery, Georgetown University Medical Center, 3800 Reservoir Road NW, Washington, DC 20007-2197.

[¶]Present address: Department of Molecular Pharmacology, Merck Research Laboratories, Merck & Co., 770 Sumneytown Pike Road, West Point, PA 19486.

^{||}To whom correspondence should be addressed. E-mail: nobentk@nidcd.nih.gov.

bacterial artificial chromosome (BAC) libraries. We screened the ES-129/SvJ I BAC library by PCR with the flanking recombinant markers (*D3Mit85*, *D3Mit260*, *D3Mit259*, and *D3Mit292*). Probes from the BAC ends of the ES-129/SvJ I BAC clones were used to screen the RPCI-23 library by hybridization. BAC clones were sized by restriction endonuclease digestion with *NotI* (NEB) followed by pulsed-field gel electrophoresis (PFGE) on a Chef-DRII apparatus (Bio-Rad). We sequenced BAC ends with vector-specific primers by using BigDye terminator chemistry (Applied Biosystems) and an ABI 377 sequencer (Applied Biosystems). To confirm the chromosomal location of each identified clone and to establish the orientation of Sp6 and T7 ends, we developed sequence-tagged sites (STSs), primer sets, and probes from the end sequences of BAC clones and mapped them to the predicted *Va'* physical interval by using PCR cross-screening experiments and Southern blot hybridizations. Overlaps among individual BAC clones were confirmed by fingerprinting with *HindIII* and/or *EcoRI* single or double digestions.

Gene Identification and Mutation Analysis. Draft sequences from RP23-108E10 and RP23-121J1 BAC clones were generated by the Department of Molecular Genetics, Albert Einstein College of Medicine Genome Center, through the TRANSHI BAC Sequencing Program (www.nih.gov/science/models/bacsequencing) and released into GenBank (accession nos. AC068947 and AC079941). BLAST searches of the EST database with these genomic sequences identified a cluster of mouse ESTs with high similarity to the full-length human cDNA clone AK001868. To obtain the homologous mouse sequence, we sequenced the longest EST clones AI787597 and AA756265. We designed primers and performed RT-PCR on C57BL/6J-derived brain cDNA to establish the mouse *Mcoln3* cDNA sequence (GenBank accession no. AY083531). We deduced its genomic structure by aligning the mouse and human cDNA against genomic sequences by using BLASTN searches and DNA-Pustell matrix alignments (MACVECTOR Version 6.0, Oxford Molecular). To identify mutations, genomic DNA from wild-type (C57BL/10J and C57BR/cdJ) and mutant (*Va/Va* and *Va^f/Va^f*) strains was used to amplify by PCR exon-specific products by using primer pairs complementary to flanking intronic sequences. PCR was carried out by using the Advantage cDNA polymerase mix (CLONTECH) according to the manufacturer's instructions. PCR products were gel purified following the Qiagen (Chatsworth, CA) gel extraction kit protocol and sequenced by using the BigDye chemistry on an ABI 377 automated sequencer. Wild-type and mutant sequences were compared by using SEQUENCHER Version 3.0 (Gene Codes, Ann Arbor, MI) software. Primers to amplify across the *Va* 1255G → C mutation are as follows: 5'-1138-TCAACTATGCTCGTGTGGC-3' (forward), 5'-1312-GGTAAGGCCAGCACAATCC-3' (reverse). Primers to amplify across the *Va^f* 1085T → C mutation are as follows: 5'-970-CACTACAAGAAGGAAGTTTCGG-3' (forward), 5'-intrinsic-GCCCAGAAATTTTTCACAGTTTGG-3' (reverse). To identify mutations in *+/Va^f* and *Va^f/Va^f*-derived cDNA, poly(A)⁺ RNA was isolated from the brain and spleen according to the Oligotex Direct mRNA kit protocol (Qiagen), and reverse transcribed with an oligo(dT) primer by using the SuperScript Preamplification System (Invitrogen). RT-PCR was carried out and resulting products were directly sequenced.

Phalloidin Staining. Cochlear ducts were dissected in Leibovitz's L-15 medium (Invitrogen) from wild-type, *Va^f*, and *Va* mice. Ducts were fixed in 4% paraformaldehyde for 2 h at room temperature and microdissections were performed to isolate the OC. Tissues were permeabilized in 0.5% Triton X-100 in PBS for 30 min, washed twice in PBS for 10 min, and then stained with 2 μg/ml fluorescein-conjugated phalloidin (Sigma) in PBS for 20

min. After three 10-min washes in PBS, samples were mounted by using the ProLong Antifade kit (Molecular Probes) and examined with a laser scanning confocal microscope (LSM 510, Zeiss).

Immunocytochemistry. To obtain antibodies against *Mcoln3* (GenBank accession no. AY083531), rabbits were immunized (Covance Research Products, Denver, PA) against synthetic peptide 1, NH₂-446-RVSECLFSLINGDDMFS-COOH, and peptide 2, NH₂-529-KDLPNSGKYRLEDDPPGSL-COOH (Princeton Biomolecules, Langhorne, PA). Immunocytochemistry was performed as described (14). OCs were dissected as described above. After permeabilization in 0.5% Triton X-100 for 30 min, samples were washed three times in PBS for 10 min and incubated in 5% normal goat serum (Life Technologies, Grand Island, NY) and 2% BSA (ICN) in PBS for 2 h to block nonspecific binding sites. After incubation with primary antibodies at 3–6 μg/ml in blocking solution for 2 h at room temperature, samples were washed several times in PBS and incubated in a 1:200 dilution of the fluorescein-conjugated anti-rabbit IgG secondary antibody (Amersham Pharmacia Biotech, Uppsala) for 40 min. Samples were mounted by using the ProLong Antifade kit and examined with a laser scanning confocal microscope (LSM 510, Zeiss). Preimmune sera and preincubation of primary antibody with an excess of immunogenic peptide were used as negative controls. Some samples were stained for actin with rhodamine-conjugated phalloidin. We obtained the same results (Fig. 4) with affinity-purified (Covance Research Products) antisera PB221 and PB220 raised against peptide 1, and antisera HL4559 and HL4560 raised against peptide 2 (Fig. 4).

GenBank Accession Numbers. Mouse mucolin-1 (*Mcoln1*), AF302009; human mucolin-1 (*MCOLN1*), AF249319; mouse mucolin-2 (*Mcoln2*), AY083532; human mucolin-2 (*MCOLN2*), AY083533; mouse mucolin-3 (*Mcoln3*), AY083531; human mucolin-3 (*MCOLN3*), AF475085; *Drosophila* CG8743, AAF49118; *Caenorhabditis elegans* CUP-5, AF338583; Pkd2, AF014010; and TRP, JU0092. Genomic clones containing *Mcoln2* and *Mcoln3*, AC068947 (RP23-108E10), and AC079941 (RP23-121J1).

Results

Perinatal Cochlea Hair Cell Defects in *Va* and *Va^f* Mutants. Previous ultrastructural studies showed hair cell degeneration in 14-day-old [postnatal day 14 (P14)] *Va^f* mutants (12). To determine the onset and extent of the hair cell defects in both alleles, we examined phalloidin-stained whole mount OC preparations with scanning laser confocal microscopy. The first signs of abnormalities were detected in *Va^f/Va^f* and as early as embryonic day 17.5 (E17.5), when the growing microvilli of both inner hair cells (IHCs) and outer hair cells (OHCs) show an irregular arrangement (Fig. 1D). Occasionally, gaps were observed in the row of IHCs, indicating signs of degeneration (Fig. 1D, arrow). At P5, stereocilia bundles of IHCs and OHCs seem to have grown to their normal length but they appear in small clumps at the top of some hair cells, showing a disorganized pattern (Fig. 1H) rather than the normal arrangement observed in littermate controls (Fig. 1E). Stereocilia disorganization in both IHCs and OHCs continued to progress from P5 to P11 when many of them appear missing through the length of the OC, and extensive fusion and clumping are apparent (Fig. 3L, arrowhead). We also examined HCs at the level of the cuticular plate but no irregularities were detected; occasionally, however, we noticed an extrusion of hair cell bodies through the reticular lamina and an abnormal cytoplasmic architecture of the hair cell body (data not shown). In *+/Va* we observed a similar progressive disorganization, with stereociliar bundles of both IHCs and OHCs




Fig. 1. Development of cochlear hair cells in varitint-waddler mutants. Labeling of cochlear hair cells F-actin by FITC-phalloidin at E17.5 (A–D), P5 (E–H), and P11 (I–L). Shown are optical sections through the OC at the level of the stereocilia. Normal hair cells can be distinguished by E17.5 as a regular array of microvilli from which ordered rows of stereocilia bundles develop; in wild-type mice, hair cell stereocilia are V-shaped in OHCs (top three rows), and straight in IHCs (bottom row) (A, E, and I). In $+/-Va^J$ mutants hair cell bundles appear mostly normal at E17.5 (B); disorganization of IHC stereocilia is severe by birth and continues to progress from P5 (F) to P11 (J); only minor signs of disorganization are noticeable in OHC bundles by P5 (F), but disorganization of the OHC bundle continues to progress, becoming more pronounced by P11 (J). In $+/-Va$ mutants, IHC and OHC stereociliar bundles are equally disorganized at all time points (C, G, and K). In Va^J/Va^J mutants, stereocilia disorganization is apparent in both IHCs and OHCs at E17.5 (D), and progresses from P5 (H) to P11 (L). In all mutant genotypes, by P11 many stereocilia appear missing and extensive fusion and clumping are apparent (J–L, arrowheads). The spatial organization of hair cells in the OC in all mutants remains unaltered with three rows of OHCs and one row of IHCs. (Bars, 10 μ m.)

becoming equally disorganized at all time points (Fig. 1 C, G, and K). The least severe pathology is seen in $+/-Va^J$, in which the general organization of the microvilli appears mostly normal at E17.5 (Fig. 1B). However, disruption of the stereocilia bundle is apparent by birth and mainly in IHCs, where disorganization of the bundle remains severe throughout development (Fig. 1F and J). Only some minor signs of disorganization are noticeable in the OHC bundles at P5 (Fig. 1F) but stereocilia disorganization continues to progress, becoming more pronounced by P11 (Fig. 1J). The progression of hair cell defects from base to apex, along its developmental gradient, and the perinatal expression of the phenotype attributes to *Va* a critical role during early steps of hair cell differentiation.

The *Va^J* Critical Interval Spans 350 kb and Contains Three Genes.

Previous linkage analyses placed *Va* to distal chromosome 3 (15), and we recently refined the *Va^J* map position to a 0.14-centimorgan interval (13). To clone *Va*, we established a physical map with BAC clones, spanning an estimated physical distance of not more than 350 kb, across the *Va^J* recombinant interval (Fig. 2). Two overlapping BAC clones (RP23–121J1 and RP23–108E10), positive for the recombinant flanking markers, were chosen for sample sequencing. Homology searches with genomic sequences from these clones identified the previously known lysophosphatidic acid receptor gene, *Edg7* (16), a full-length mouse mRNA AK014467, and several overlapping mouse ESTs representing a cDNA not previously described. AK014467 and the mouse transcript shared significant amino acid similarities (67% and 73%, respectively) to human mucolipin-1 (*MCOLN1*, AF249319) and were subsequently designated *Mcoln2* (AY083532) and *Mcoln3* (AY083531), respectively.

Mucolipin-3 (*Mcoln3*) Encodes a Predicted Ion Channel. *Mcoln3* has an ORF of 1,662 bp and encodes a protein of 553 aa with a predicted molecular mass of \approx 64 kDa (Fig. 5, which is published as supporting information on the PNAS web site, www.pnas.org). The deduced amino acid sequence shares the highest degree of similarity with *Mcoln2* (77%) and *Mcoln1* (74%). Secondary structure analyses predict that *Mcoln3*




Fig. 2. Physical map of the *Va^J* critical region. The thick horizontal gray line (Bottom) represents the *Va^J* critical interval defined by the polymorphic *Mit* markers on mouse chromosome 3. cM, centimorgan. A contig of 15 overlapping BAC clones is represented by horizontal lines; RPCI-23 BAC clones are shown in blue, Incyte Genomics BAC clones are in black, and BAC clones used for sample sequencing are in purple. Coordinates and corresponding sizes appear next to each BAC clone. SP6 and T7 ends of BACs are indicated by S or T, respectively. BAC ends used to derive probes for screening of the RPCI-23 BAC library are indicated by \wedge . Dashed lines in red indicate anchored SP6 and T7 BAC ends that have been used in PCR cross-screening and/or Southern blot experiments to confirm overlaps among BAC clones. Genes that map within the candidate region are shown with an arrow indicating transcription orientation. *Mcoln3* exons are indicated. Genomic clones containing *Mcoln2* and *Mcoln3*, AC068947 (RP23–108E10), and AC079941 (RP23–121J1).




Fig. 3. Sequence analysis of *Mcoln3*. (A) Schematic representation of predicted structure of *Mcoln3*. Six putative transmembrane domains (S1–S6) and a putative pore region (amino acids 480–505; in purple) are shown. Mutations in *Mcoln3* are indicated by red dots. Blue lines represent regions of *Mcoln3* containing polyclonal antibody recognition sites: PB221 and PB220 antisera were raised against amino acids 446–462, HL4559, and HL4560 against amino acids 529–548. (B) CLUSTALW alignment of the mucolipin family. Multiple sequence alignment of *Mcoln3*, *Mcoln1*, *Mcoln2*, *C. elegans* CUP-5, and *Drosophila* CG743 is shown with *Pkd2* (amino acids 478–682) and *TRP* (amino acids 430–665). Putative transmembrane domains (S1–S6) are indicated by thick blue lines. Predicted ion transport domain and TRPL motif (PS50272) of *Mcoln3* are located between amino acids 337–501 and amino acids 317–505, respectively. Conserved amino acids across the *Mcoln3* TRPL region are shaded yellow. Sites of mutations in *Mcoln3* are shown in red and in CUP-5 in teal. Amino acid positions are given on the right. (C) Mutation analysis. Sequence chromatographs showing nucleotide sequence and translation across the sites of mutations in C57BL/10J, *Va/Va*, and *Va¹/Va¹* genomic DNA. Nucleotide changes are shown in red.

contains six transmembrane domains (S1–S6) with short cytoplasmic amino and carboxy termini (Fig. 3A). Sequence motif analyses identify an ion-transport domain (Pfam00520) and a transient-receptor-potential-like (TRPL) motif (PS50272) between S3 and S6, as well as a putative pore region between S5 and S6 (PS50273) (Fig. 3B). Sequence similarities of *Mcoln3* with *Drosophila* CG8743 (63%) and *C. elegans* CUP-5 (55%) homologues are significant, with the highest degree of conservation being observed across the TRPL motif (74% and 73%, respectively). Amino acid sequence compar-

ison of *Mcoln3* with *Pkd2* and *TRP* reveals only limited but significant similarity (49% and 32%, respectively) across the TRPL region (Fig. 3B).

The Varitint-Waddler Phenotype Is Associated with Mutations in *Mcoln3*. All 12 coding exons of *Mcoln3* were analyzed for mutations by sequence analyses of PCR products amplified from the genomic DNA of mutant (*Va/Va* and *Va¹/Va¹*) and control strains (C57BL/10J and C57BL/6J; Fig. 3C). The *Va* allele carries a 1255G → C transversion in exon 10 leading to an




Fig. 4. Localization of *Mcoln3* in mouse and rat OC by immunofluorescence. Shown are cross-sections through the OC showing the labeling of IHCs for *Mcoln3*. (A–E) Mouse OC at P11, and optical sections at the level of the cell body of IHCs. In A a single row of IHCs and three rows of OHCs (1, 2, and 3) are presented. (A, D, and E) PB221 labeling for *Mcoln3*. The cytoplasm of IHCs is intensively labeled in wild type (A), $+/Va'$ (D), and Va'/Va' (E); staining is absent after incubation with preimmune serum (B) and excess specific peptide (C). Some labeling is also observed in the cytoplasm of OHCs (A, D, and E), and under the cuticular plate (not shown). (F–J) Rat OC at 4 weeks of age, and optical sections at the level of cell bodies (F–H) and the cuticular plate (I and J) of IHCs. All four anti-*Mcoln3* antisera, PB220 (F and I), PB221 (J), HL4459 (G), and HL4460 (H) showed immunoreactivity in the cytoplasm of IHCs. In the cytoplasm, labeling appears as a punctuate pattern (*, I) throughout the IHC bodies, and it is also detected in the subcuticular region (dashed lines, I), the pericuticular necklace (white arrows, J), and in the IHC bundles (white arrowheads, J). Specificity of all four antisera was confirmed by immunoblot after bacterial expression of a partial *Mcoln3* fusion protein (data not shown). Stereocilia staining was also observed on mouse OC (data not shown). (Bars, 80 μm .)

Ala419Pro substitution in the fifth predicted transmembrane domain of the protein (Fig. 3 A and C). The mutation in Va' is a 1085T \rightarrow C transition in exon 8 resulting in an Ile362Thr substitution in the second predicted extracellular loop (Fig. 3 A and C). Interestingly, we also detected the 1255G \rightarrow C nucleotide change in Va' , suggesting that Va' arose in cis to *Va* (Fig. 3C). These nucleotide changes cosegregated with Va' in the critical recombinants, and were not present in the parental or other representative inbred strains. No mutations were found in the coding regions of *Edg7* and *Mcoln2*.

***Mcoln3* Localizes to Vesicular Compartments and Stereocilia in Cochlea Hair Cells.** To gain insights into the cellular function of *Mcoln3*, we determined its subcellular location. By using polyclonal antibodies directed against either an extracellular or cytoplasmic epitope of *Mcoln3* (Fig. 3A), the distribution of the protein in the OC was determined in wild-type (Fig. 4A) and

mutant mice (Fig. 4 D and E), and adult rat (Fig. 4 F–J). In the mouse, *Mcoln3* is highly expressed in the cytoplasm of IHCs and OHCs where labeling appears as a punctuate pattern throughout the hair cell bodies (Fig. 4A). A similar staining was also observed in the cytoplasm of IHCs and some OHCs of Va'/Va' and $+/Va'$ mice (Fig. 4 D and E). Immunoreactivity in the adult OC of the rat was specific and concentrated to cytoplasmic compartments of IHCs with all four anti-*Mcoln3* antisera that we generated (Fig. 4 F–J). Fluorescence labeling was also detected in the subcuticular region (Fig. 4I) and the pericuticular necklace (Fig. 4J). In addition, modest immunoreactivity localizes to the plasma membrane of the stereocilia (Fig. 4J). Consistent with circling behavior in *Va* and Va' mutants, we also detected *Mcoln3* expression in vestibular hair cells (data not shown).

Discussion

A high-resolution genetic and physical mapping approach localized *Va* to a minimal region of 350 kb, in which three genes were identified. The only nucleotide changes were found in *Mcoln3*, and those were absent from parental controls (C57BR/cdJ, C57L/J, C58/J, C57BL/6J, C57BL/10J, C57BL/KS, C57BL/ScSnJ, and STOCK-*a/a ma ft/ma ft*) and in other strains that are representative members of different subgroups of inbred mouse strains (17) such as Castle's mice (CBA/CaJ, 129/SvJ, DBA/2J, BALB/cByJ, and AKR/J), Swiss mice (FVB/FnJ and NOD/LtJ) and wild-derived mice from different continents (PERC/Ei, MOLF/Ei, CZECHII/Ei, and CAST/Ei) suggesting that the sequence alterations are causative mutations. Moreover, similar pathogenic mutations were found in *Cup-5* (G401E and G473D) and *MCOLN1* (D362Y and V446L). The Ala419Pro substitution in *Va* in the fifth transmembrane domain, located near the predicted pore region, is likely to cause a gain-of-function or dominant-negative effect (18), although other mechanisms, such as the partial loss of functionality, cannot be entirely ruled out. Va' was first recognized as a less variegated offspring from a *Va* linkage test cross, and subsequent breeding showed that the deviant was a somatic and germ-line mosaic and allelic to *Va* (10). The presence of two missense mutations in *Mcoln3* in Va' argues that the 1085T \rightarrow C transition arose in cis to *Va*. Given the consistently milder phenotypes in Va' , it suggests that Ile362Thr acts as an intragenic suppressor mutation. However, definitive proof of the causative nature of the missense mutations awaits further transgenic experiments and molecular functional studies.

Mucopolipins constitute a newly recognized family of cation channel proteins with homologues in mouse (*Mcoln1*), *D. melanogaster* (CG8743), and *C. elegans* (CUP-5). Mutations in human *MCOLN1* cause the neurodegenerative lysosomal disorder mucopolipidosis type IV (OMIM 252650) (19–22), and loss-of-function mutations in *C. elegans*-CUP-5 lead to endocytosis defects, formation of large lysosomal vacuoles, and increased apoptosis (23, 24). Here, we describe two additional members, *Mcoln2* and *Mcoln3*, of the mammalian gene family. The actual role of *Mcoln2* is not known and may be defined by either cellular or genetic means. The motif and sequence similarities of *Mcoln3* with *C. elegans* CUP-5 and human *MCOLN1* as well as the punctuate staining of cytoplasmic compartments and the pericuticular necklace suggest that *Mcoln3* is associated with vesicular structures (25), and thus plays a critical role in vesicles. Defects in vesicle function often result in skin pigmentation abnormalities such as seen in the dilute, leaden, chocholate, or ashen mutants in which mutations in myosin Va (*MyoVa*), melanophilin (*Mlph*), *Rab38*, and *Rab27a* affect transport and trafficking of late-stage melanosomes (26–29). Based on the motif similarities with ion channels, we hypothesize that *Mcoln3* is involved in vesicular and/or intracellular ion homeostasis in inner ear hair cells and melanocytes.

Va homozygotes were reported to be less viable (9), and we recently showed that *Va'* homozygotes on the C57BL/6J background (after six backcross generations) have only a 34% chance of survival (13). Possibly, embryonic melanocytes fail to differentiate, migrate, or survive, and subsequently, downstream apoptotic events, similar to those observed in the null allele of *CUP-5* (24), may cause the embryonic lethal phenotype. This observation and our generation of a C57BL/6J congenic strain (B6.*Va'*) present an additional avenue to further characterize the cellular function of *Mcoln3* and its dependence on the genetic background.

Mucolipins show sequence and motif similarities to the TRP ion channel family (30–32), including the polycystin-2 (PKD2) protein family of nonselective intracellular ion channels (33–35). TRP channels are characterized by a six-transmembrane-domain topology and their permeability to cations, including Ca²⁺ (31), a characteristic that is shared with the mechanosensitive transduction channel in vertebrate hair cells. Proteins of the TRP family are involved in the transduction of sensory stimuli in vision (36), olfaction (37), thermoreception (38), osmoregulation (39), and mechanosensation (40). Two members of the TRP gene family, *NompC* and *TRPV4* (former *Osm-9*), were shown to

be involved in mechanotransduction in *D. melanogaster* and *C. elegans*, respectively (37, 40), and more recently the murine homolog of *TRPV4* was localized to inner ear hair cells (41). Our localization of *Mcoln3* to the stereocilia, however, leads to the interesting hypothesis that this predicted channel might also be involved in sensory transduction.

Several lines of evidence argue for a cell-autonomous function of *Mcoln3*: (i) independent defects in the OC and stria vascularis as shown (12), (ii) erratic circling behavior indicative of vestibular hair cell defects, and (iii) localization of *Mcoln3* to cochlea and vestibular hair cells. Thus, *Va* encodes an interesting molecular link between inner ear hair cells and melanocytes. Finally, human *MCOLN2* and *MCOLN3* are candidate genes for inherited and/or sporadic neurosensory disorders.

We thank Bill Pavan, Mark Fogg, Feng Qian, Emma Morton-Bours, Keith Vokey, and Susan Cole for discussions, Doris Wu, Dennis Drayna, Bob Wenthold, and Heinz Arnheiter for valuable comments on the manuscript, Alfredo Calderon for technical assistance, and Melissa Irby and Jimmy Fiallos for animal colony management. This work was supported by the intramural program of the National Institute on Deafness and Other Communication Disorders.

- Steel, K. P. & Kros, C. J. (2001) *Nat. Genet.* **27**, 143–149.
- Geissler, E. N., Ryan, M. A. & Housman, D. E. (1988) *Cell* **55**, 185–192.
- Chabot, B., Stephenson, D. A., Chapman, V. M., Besmer, P. & Bernstein, A. (1988) *Nature* **335**, 88–89.
- Matsui, Y., Zsebo, K. M. & Hogan, B. L. (1990) *Nature* **347**, 667–669.
- Huang, E., Nocka, K., Beier, D. R., Chu, T. Y., Buck, J., Lahm, H. W., Wellner, D., Leder, P. & Besmer, P. (1990) *Cell* **63**, 225–233.
- Hodgkinson, C. A., Moore, K. J., Nakayama, A., Steingrimsson, E., Copeland, N. G., Jenkins, N. A. & Arnheiter, H. (1993) *Cell* **74**, 395–404.
- Cable, J., Huszar, D., Jaenisch, R. & Steel, K. P. (1994) *Pigment Cell Res.* **7**, 17–32.
- Cable, J., Jackson, I. J. & Steel, K. P. (1995) *Mech. Dev.* **50**, 139–150.
- Cloudman, A. M. & Bunker, L. E. (1945) *J. Hered.* **36**, 258–263.
- Lane, P. W. (1972) *J. Hered.* **63**, 135–140.
- Deol, M. S. (1954) *J. Genet.* **52**, 562–588.
- Cable, J. & Steel, K. P. (1998) *Hear. Res.* **123**, 125–136.
- Kim, H. J., Jackson, T. & Noben-Trauth, K. (September 18, 2002) *J. Assoc. Res. Otolaryngol.*, 10.1007/s10162-002-3011-0.
- Belyantseva, I. A., Adler, H. J., Curi, R., Frolenkov, G. I. & Kachar, B. (2000) *J. Neurosci.* **20**, RC116.
- Mobraaten, L. E., Bunker, H. P., DeMaeyer-Guignard, J., DeMaeyer, E. & Bailey, D. W. (1984) *J. Hered.* **75**, 233–234.
- Contos, J. J. & Chun, J. (2001) *Gene* **267**, 243–253.
- Beck, J. A., Lloyd, S., Hafezparast, M., Lennon-Pierce, M., Eppig, J. T., Festing, M. F. & Fisher, E. M. (2000) *Nat. Genet.* **24**, 23–25.
- Lester, H. A. & Karschin, A. (2000) *Annu. Rev. Neurosci.* **23**, 89–125.
- Bargal, R. & Bach, G. (1997) *J. Inherit. Metab. Dis.* **20**, 625–632.
- Bargal, R., Avidan, N., Ben-Asher, E., Olender, Z., Zeigler, M., Frumkin, A., Raas-Rothschild, A., Glusman, G., Lancet, D. & Bach, G. (2000) *Nat. Genet.* **26**, 118–123.
- Sun, M., Goldin, E., Stahl, S., Falardeau, J. L., Kennedy, J. C., Acierno, J. S., Jr., Bove, C., Kaneski, C. R., Nagle, J., Bromley, M. C., et al. (2000) *Hum. Mol. Genet.* **9**, 2471–2478.
- Bassi, M. T., Manzoni, M., Monti, E., Pizzo, M. T., Ballabio, A. & Borsani, G. (2000) *Am. J. Hum. Genet.* **67**, 1110–1120.
- Fares, H. & Greenwald, I. (2001) *Nat. Genet.* **28**, 64–68.
- Hersh, B. M., Hartweg, E. & Horvitz, H. R. (2002) *Proc. Natl. Acad. Sci. USA* **99**, 4355–4360.
- Kachar, B., Battaglia, A. & Fex, J. (1997) *Hear. Res.* **107**, 102–112.
- Loftus, S. K., Larson, D. M., Baxter, L. L., Antonellis, A., Chen, Y., Wu, X., Jiang, Y., Bittner, M., Hammer, J. A., III, & Pavan, W. J. (2002) *Proc. Natl. Acad. Sci. USA* **99**, 4471–4476.
- Matesic, L. E., Yip, R., Reuss, A. E., Swing, D. A., O'Sullivan, T. N., Fletcher, C. F., Copeland, N. G. & Jenkins, N. A. (2001) *Proc. Natl. Acad. Sci. USA* **98**, 10238–10243.
- Wu, X. S., Rao, K., Zhang, H., Wang, F., Sellers, J. R., Matesic, L. E., Copeland, N. G., Jenkins, N. A. & Hammer, J. A., III (2002) *Nat. Cell Biol.* **4**, 271–278.
- Wilson, S. M., Yip, R., Swing, D. A., O'Sullivan, T. N., Zhang, Y., Novak, E. K., Swank, R. T., Russell, L. B., Copeland, N. G. & Jenkins, N. A. (2000) *Proc. Natl. Acad. Sci. USA* **97**, 7933–7938.
- Littleton, J. T. & Ganetzky, B. (2000) *Neuron* **26**, 35–43.
- Clapham, D. E., Runnels, L. W. & Strubing, C. (2001) *Nat. Rev. Neurosci.* **2**, 387–396.
- Montell, C. (2001) *Sci. STKE*, <http://stke.sciencemag.org/cgi/content/full/OC.sigtrans;2001/90/re1>.
- Gonzalez-Perret, S., Kim, K., Ibarra, C., Damiano, A. E., Zotta, E., Batelli, M., Harris, P. C., Reisin, I. L., Arnaout, M. A. & Cantiello, H. F. (2001) *Proc. Natl. Acad. Sci. USA* **98**, 1182–1187.
- Hanaoka, K., Qian, F., Boletta, A., Bhunia, A. K., Piontek, K., Tsiokas, L., Sukhatme, V. P., Guggino, W. B. & Germino, G. G. (2000) *Nature* **408**, 990–994.
- Koulen, P., Cai, Y., Geng, L., Maeda, Y., Nishimura, S., Witzgall, R., Ehrlich, B. E. & Somlo, S. (2002) *Nat. Cell Biol.* **4**, 191–197.
- Zhu, X., Jiang, M., Peyton, M., Boulay, G., Hurst, R., Stefani, E. & Birnbaumer, L. (1996) *Cell* **85**, 661–671.
- Colbert, H. A., Smith, T. L. & Bargmann, C. I. (1997) *J. Neurosci.* **17**, 8259–8269.
- Peier, A. M., Moqrich, A., Hergarden, A. C., Reeve, A. J., Andersson, D. A., Story, G. M., Earley, T. J., Dragoni, I., McIntyre, P., Bevan, S. & Patapoutian, A. (2002) *Cell* **108**, 705–715.
- Strotmann, R., Harteneck, C., Nunnenmacher, K., Schultz, G. & Plant, T. D. (2000) *Nat. Cell Biol.* **2**, 695–702.
- Walker, R. G., Willingham, A. T. & Zuker, C. S. (2000) *Science* **287**, 2229–2234.
- Liedtke, W., Choe, Y., Marti-Renom, M. A., Bell, A. M., Denis, C. S., Sali, A., Hudspeth, A. J., Friedman, J. M. & Heller, S. (2000) *Cell* **103**, 525–535.